{"id":"cpgj602","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Nausea"},{"rate":"5-10%","effect":"Diarrhea"},{"rate":"5-10%","effect":"Vomiting"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By inhibiting SGLT2, CPGJ602 reduces glucose reabsorption in the kidneys, thereby lowering blood glucose levels. This mechanism is particularly beneficial for patients with type 2 diabetes.","oneSentence":"CPGJ602 is a small molecule that targets the SGLT2 receptor.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T03:29:27.034Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes"}]},"trialDetails":[{"nctId":"NCT04466254","phase":"PHASE2","title":"Efficacy and Safety Study of Combination of CPGJ602 and Chemotherapy, in First Line, With Wild KRAS/NRAS/BRAF in Metastatic Colorectal Cancer","status":"UNKNOWN","sponsor":"Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.","startDate":"2020-12-07","conditions":"Metastatic Colorectal Cancer","enrollment":75},{"nctId":"NCT03356158","phase":"PHASE1","title":"A Study of Recombinant Anti-EGFR Monoclonal Antibody in Patients With Metastatic Colorectal Cancer","status":"UNKNOWN","sponsor":"Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.","startDate":"2017-11-15","conditions":"Metastatic Colorectal Cancer","enrollment":21}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"CPGJ602","genericName":"CPGJ602","companyName":"Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.","companyId":"sunshine-guojian-pharmaceutical-shanghai-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"CPGJ602 is a small molecule that targets the SGLT2 receptor. Used for Type 2 diabetes.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":2,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}